An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern
Brazil Cuts Selic Rate to 14% as Inflation Eases but Risks Persist
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Gold Prices Surge 7% as Dollar Falls, Fed Rate Hike Bets Ease
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls
China Trade Surplus Beats Forecasts in July as Exports Stay Strong
3 clinical-grade skincare creams you really shouldn’t buy online
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Asian Currencies Hold Steady as US Dollar Nears Seven-Week Low Ahead of Key Jobs Data
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



